Buys | $0 | 0 | 0 |
Sells | $841 | 1 | 100 |
Myers Laurie | EVP and COO | 0 | $0 | 1 | $841 | $-841 |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Over the last 12 months, insiders at Cingulate Inc. have bought $0 and sold $841 worth of Cingulate Inc. stock.
On average, over the past 5 years, insiders at Cingulate Inc. have bought $458,420 and sold $11,525 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $3,349 was made by Callahan Jennifer L. (Corporate Controller) on 2023‑09‑15.
2024-08-15 | Sale | Myers Laurie | EVP and COO | 202 0.0346% | $4.17 | $841 | -5.83% | |
2023-09-15 | Callahan Jennifer L. | Corporate Controller | 5,000 0.031% | $0.67 | $3,349 | -91.95% | ||
2023-08-11 | Werth Peter J. | director | 1.82M 16.1208% | $0.55 | $1M | -88.68% | ||
2023-05-15 | Callahan Jennifer L. | Corporate Controller | 2,000 0.0184% | $1.01 | $2,020 | -61.39% | ||
2023-05-12 | Callahan Jennifer L. | Corporate Controller | 4,000 0.0374% | $1.08 | $4,320 | -62.62% | ||
2022-12-16 | Schaffer Shane J. | Chief Executive Officer | 10,000 0.0879% | $1.02 | $10,166 | -11.54% | ||
2022-12-14 | Callahan Jennifer L. | Corporate Controller | 7,548 0.0728% | $0.99 | $7,468 | +0.16% | ||
2022-12-14 | Schaffer Shane J. | Chief Executive Officer | 13,267 0.1305% | $1.01 | $13,400 | +0.16% | ||
2022-12-13 | Werth Peter J. | director | 28,934 0.2505% | $0.98 | $28,422 | -9.36% | ||
2022-12-13 | Schaffer Shane J. | Chief Executive Officer | 1,733 0.0154% | $1.01 | $1,750 | -9.36% | ||
2022-11-29 | Callahan Jennifer L. | Corporate Controller | 1,530 0.0144% | $0.98 | $1,499 | +0.64% | ||
2022-11-28 | Callahan Jennifer L. | Corporate Controller | 3,487 0.0304% | $0.98 | $3,417 | -7.00% | ||
2022-11-23 | Myers Laurie | EVP and COO | 1,111 0.0098% | $0.90 | $1,000 | +2.74% | ||
2022-11-23 | Gilgallon Craig S. | EVP, GC and Secretary | 3,575 0.0295% | $0.84 | $3,003 | +2.74% | ||
2022-11-22 | GIVENS GREGG WM | director | 85,000 0.766% | $0.88 | $74,851 | +6.90% | ||
2022-09-08 | Callahan Jennifer L. | Corporate Controller | 3,500 0.0312% | $1.50 | $5,250 | -33.89% | ||
2022-09-06 | Werth Peter J. | 74,500 0.6459% | $1.52 | $113,225 | -36.13% | |||
2022-09-01 | Myers Laurie | EVP and COO | 636 0.0057% | $1.57 | $999 | -36.13% | ||
2022-06-01 | Myers Laurie | EVP and COO | 200 0.0018% | $1.18 | $236 | -6.90% | ||
2022-05-17 | Myers Laurie | EVP and COO | 200 0.0017% | $1.21 | $242 | -12.19% |
Increased Positions | 6 | +46.15% | 64,535 | +129.05% |
Decreased Positions | 6 | -46.15% | 23,827 | -47.65% |
New Positions | 3 | New | 27,711 | New |
Sold Out Positions | 4 | Sold Out | 21,466 | Sold Out |
Total Postitions | 13 | company.total | 90,714 | +81.41% |
Commonwealth Equity Services, Llc | $154.00 | 1.43% | 43,022 | +31,746 | +281.54% | 2024-12-31 |
Geode Capital Management, Llc | $98.00 | 0.91% | 27,323 | +27,323 | New | 2024-12-31 |
Ubs Group Ag | $44.00 | 0.41% | 12,196 | -1,553 | -11.29% | 2024-12-31 |
Alphamark Advisors, Llc | $18.00 | 0.17% | 5,010 | +5,000 | +50,000% | 2024-12-31 |
Bank Of America Corp /De/ | $7.00 | 0.07% | 1,956 | +78 | +4.15% | 2024-12-31 |
Tower Research Capital Llc (Trc) | $3.00 | 0.03% | 764 | -808 | -51.4% | 2024-12-31 |
Citigroup Inc | $1.00 | 0.01% | 387 | +387 | New | 2024-12-31 |
Osaic Holdings, Inc. | $0 | <0.01% | 55 | 0 | 0% | 2024-12-31 |
Sbi Securities Co., Ltd. | $0 | 0% | 1 | +<1 | New | 2024-12-31 |
Fmr Llc | $0 | 0% | 0 | -352 | Sold Out | 2024-12-31 |